Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Catalyst Pharmaceutical Partners, Inc.    CPRX   US14888U1016

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
3.35(c) 3.33(c) 3.34(c) 3.42(c) 3.65(c) Last
1 685 436 768 886 563 684 479 121 2 362 101 Volume
+9.48% -0.60% +0.30% +2.40% +6.73% Change
More quotes
Company
Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company, which focuses on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system with a focus on the treatment of drug addiction and... 
More about the company
Surperformance© ratings of Catalyst Pharmaceutical Pa
Trading Rating : Investor Rating : -
More Ratings
Chart CATALYST PHARMACEUTICAL PA
Duration : Period :
Catalyst Pharmaceutical Pa Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 -
EBIT 2014 -14,6 M
Net income 2014 -16,1 M
Debt 2014 -
Yield 2014 -
Sales 2015 -
EBIT 2015 -14,2 M
Net income 2015 -17,8 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 0
Capi. / Sales 2015 0
Capitalization 252 M
More Financials
Latest news on CATALYST PHARMACEUTICAL PA
01/27 CATALYST PHARMACEUTICAL PARTNERS : Deadline Upcoming in $ 3.5 Million Settlement..
01/23 CATALYST PHARMACEUTICAL PARTNERS : Friday 1/23 Insider Buying Report: CPRX, MEIP
01/12 CATALYST PHARMACEUTICAL PARTNERS : Pharmaceuticals Provides an Update of 2015 Go..
01/05 Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Ch..
2014 Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founde..
2014 CATALYST PHARMACEUTICAL PARTNERS : Pharmaceuticals to Present at the Piper Jaffr..
2014 CATALYST PHARMACEUTICAL PARTNERS : Patent Application Titled "Method of Treating..
2014 CATALYST PHARMACEUTICAL PARTNERS : Pharmaceuticals Announces Notice of Allowance..
More news
Sector news Bio Therapeutic Drugs
01/30 PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF